Drug intelligence / Profile preview

mRNA-4106

Development stage: Phase 1
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

mRNA-4106 is an investigational, intramuscularly administered mRNA therapeutic developed by Moderna for the treatment of solid tumors. It is currently being evaluated in a Phase 1, open-label, multicenter, dose-escalation clinical trial both as a monotherapy and in combination with immune checkpoint blockade. The drug utilizes messenger RNA (mRNA) technology to induce an anti-tumor immune response by encoding specific antigens or immunomodulatory proteins within tumor cells. Its primary indication is for neoplasms (solid tumors), and it represents part of Moderna's expanding oncology pipeline[1][2][3][4].

Targets

CTA (Cancer-testis antigens)

Beyond the preview

Go deeper on mRNA-4106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-4106.

Explore the full profile